Cure8 research brief
The study presents preclinical data that an orally delivered biotherapeutic (EPICERTIN) promotes epithelial repair and reduces inflammation in a UC-relevant mouse model — a potential step toward therapies that directly enhance mucosal healing.
Researchers in IBD drug development, clinicians tracking emerging UC therapies, translational scientists focused on epithelial repair and mucosal healing
The study tested oral EPICERTIN at several doses in an oxazolone-induced colitis model (a model relevant to UC). The authors measured disease activity, weight change, histology, gene expression, epithelial and fibrotic protein markers, and immune cell populations using techniques like qRT-PCR, imaging mass cytometry, and CyTOF.
The middle dose (3 µg) showed the clearest benefit in this acute model, correlating with improved epithelial markers and reduced inflammatory and fibrotic markers. The work is preclinical (mouse model) and reports mechanistic and tissue-level outcomes rather than clinical efficacy in humans.
This supports further development but does not demonstrate safety or benefit in people with UC.
Results come from an acute oxazolone mouse model and measurements of tissue, gene, and immune markers. This is preclinical evidence; it does not demonstrate human safety or efficacy.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: National Institutes of Health, award 5R01DK123712-04; award 5R01DK123712-04
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study describes a new oral, colon‑targeted delivery system that improved outcomes in a mouse model of ulcerative colitis and shifted immune and microbiome markers—research that could inform future therapies focused...
FAP appears linked to both inflammation and fibrosis in IBD; distinguishing cellular versus extracellular FAP might help develop or validate fibrosis biomarkers that detect fibrostenotic disease.
A probe that images superoxide in inflamed colons could help researchers study oxidative stress in ulcerative colitis and potentially guide development of new biomarkers or imaging approaches.
